Filtered By:
Drug: Dexamethasone
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 8422 results found since Jan 2013.
Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
CONCLUSION: A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2.PMID:35512745 | DOI:10.3349/ymj.2022.63.5.430
Source: Yonsei Medical Journal - May 5, 2022 Category: Universities & Medical Training Authors: Jin Yeong Hong Jae-Hoon Ko Jinyoung Yang Soyoung Ha Eliel Nham Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Jin Yang Baek You Min Sohn Hyo Jung Park Beomki Lee Hee Jae Huh Eun-Suk Kang Gee Young Suh Chi Ryang Chung Kyong Ran Peck Source Type: research
Efficacy of Corticosteroid Therapy in Non-severe COVID-19 Patients with Severe Risk Factors who do not Require Supplemental Oxygen
CONCLUSION: The latest World Health Organization guidance recommends against corticosteroid treatment for non-severe patients. In this report, we showed that the early administration of corticosteroids during the non-critical phase, when oxygen supplementation is not required, was useful for the early improvement and prevention of severe disease in patients with risk factors for severe COVID-19 and worsening clinical symptoms.PMID:35400720 | DOI:10.1272/jnms.JNMS.2022_89-409
Source: Journal of Nippon Medical School - April 11, 2022 Category: Universities & Medical Training Authors: Toru Tanaka Yoshinobu Saito Takeru Kashiwada Shinji Nakamichi Masaru Matsumoto Akihiko Miyanaga Yosuke Tanaka Kazue Fujita Masahiro Seike Akihiko Gemma Source Type: research
Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
CONCLUSION: A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2.PMID:35512745 | DOI:10.3349/ymj.2022.63.5.430
Source: Yonsei Medical Journal - May 5, 2022 Category: Universities & Medical Training Authors: Jin Yeong Hong Jae-Hoon Ko Jinyoung Yang Soyoung Ha Eliel Nham Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Jin Yang Baek You Min Sohn Hyo Jung Park Beomki Lee Hee Jae Huh Eun-Suk Kang Gee Young Suh Chi Ryang Chung Kyong Ran Peck Source Type: research
Efficacy of Corticosteroid Therapy in Non-severe COVID-19 Patients with Severe Risk Factors who do not Require Supplemental Oxygen
CONCLUSION: The latest World Health Organization guidance recommends against corticosteroid treatment for non-severe patients. In this report, we showed that the early administration of corticosteroids during the non-critical phase, when oxygen supplementation is not required, was useful for the early improvement and prevention of severe disease in patients with risk factors for severe COVID-19 and worsening clinical symptoms.PMID:35400720 | DOI:10.1272/jnms.JNMS.2022_89-409
Source: Journal of Nippon Medical School - April 11, 2022 Category: Universities & Medical Training Authors: Toru Tanaka Yoshinobu Saito Takeru Kashiwada Shinji Nakamichi Masaru Matsumoto Akihiko Miyanaga Yosuke Tanaka Kazue Fujita Masahiro Seike Akihiko Gemma Source Type: research
Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
CONCLUSION: A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2.PMID:35512745 | DOI:10.3349/ymj.2022.63.5.430
Source: Yonsei Medical Journal - May 5, 2022 Category: Universities & Medical Training Authors: Jin Yeong Hong Jae-Hoon Ko Jinyoung Yang Soyoung Ha Eliel Nham Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Jin Yang Baek You Min Sohn Hyo Jung Park Beomki Lee Hee Jae Huh Eun-Suk Kang Gee Young Suh Chi Ryang Chung Kyong Ran Peck Source Type: research
Efficacy of Corticosteroid Therapy in Non-severe COVID-19 Patients with Severe Risk Factors who do not Require Supplemental Oxygen
CONCLUSION: The latest World Health Organization guidance recommends against corticosteroid treatment for non-severe patients. In this report, we showed that the early administration of corticosteroids during the non-critical phase, when oxygen supplementation is not required, was useful for the early improvement and prevention of severe disease in patients with risk factors for severe COVID-19 and worsening clinical symptoms.PMID:35400720 | DOI:10.1272/jnms.JNMS.2022_89-409
Source: Journal of Nippon Medical School - April 11, 2022 Category: Universities & Medical Training Authors: Toru Tanaka Yoshinobu Saito Takeru Kashiwada Shinji Nakamichi Masaru Matsumoto Akihiko Miyanaga Yosuke Tanaka Kazue Fujita Masahiro Seike Akihiko Gemma Source Type: research
Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
CONCLUSION: A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2.PMID:35512745 | DOI:10.3349/ymj.2022.63.5.430
Source: Yonsei Medical Journal - May 5, 2022 Category: Universities & Medical Training Authors: Jin Yeong Hong Jae-Hoon Ko Jinyoung Yang Soyoung Ha Eliel Nham Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Jin Yang Baek You Min Sohn Hyo Jung Park Beomki Lee Hee Jae Huh Eun-Suk Kang Gee Young Suh Chi Ryang Chung Kyong Ran Peck Source Type: research
Efficacy of Corticosteroid Therapy in Non-severe COVID-19 Patients with Severe Risk Factors who do not Require Supplemental Oxygen
CONCLUSION: The latest World Health Organization guidance recommends against corticosteroid treatment for non-severe patients. In this report, we showed that the early administration of corticosteroids during the non-critical phase, when oxygen supplementation is not required, was useful for the early improvement and prevention of severe disease in patients with risk factors for severe COVID-19 and worsening clinical symptoms.PMID:35400720 | DOI:10.1272/jnms.JNMS.2022_89-409
Source: Journal of Nippon Medical School - April 11, 2022 Category: Universities & Medical Training Authors: Toru Tanaka Yoshinobu Saito Takeru Kashiwada Shinji Nakamichi Masaru Matsumoto Akihiko Miyanaga Yosuke Tanaka Kazue Fujita Masahiro Seike Akihiko Gemma Source Type: research
Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
CONCLUSION: A combination of severity-adjusted dexamethasone and tocilizumab for the treatment of severe COVID-19 improved clinical recovery without increasing infectious complications or hindering the immune response against SARS-CoV-2.PMID:35512745 | DOI:10.3349/ymj.2022.63.5.430
Source: Yonsei Medical Journal - May 5, 2022 Category: Universities & Medical Training Authors: Jin Yeong Hong Jae-Hoon Ko Jinyoung Yang Soyoung Ha Eliel Nham Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Jin Yang Baek You Min Sohn Hyo Jung Park Beomki Lee Hee Jae Huh Eun-Suk Kang Gee Young Suh Chi Ryang Chung Kyong Ran Peck Source Type: research
Protective effect of excretory-secretory proteins from < em > Trichinella spiralis < /em > muscle larvae against myocardial injury in septic mice
CONCLUSION: Ts-MES are capable of protecting against myocardial injury in septic mice by reducing the production of pro-inflammatory cytokines and enhancing the levels of regulatory cytokines.PMID:35790432 | DOI:10.12122/j.issn.1673-4254.2022.06.05
Source: Journal of Southern Medical University - July 5, 2022 Category: Universities & Medical Training Authors: Y Yuan F Nian H Li H Yang Y Wu M Ma K Wang X Chen Z Zhang G Li X Yang Q Wu Source Type: research
